Casper Steenholdt

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 451 citations

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov et al. · Scandinavian Journal of Gastroenterology · 2010 · 173 citations

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Casper Steenholdt, Morten Svenson, Klaus Bendtzen et al. · Alimentary Pharmacology & Therapeutics · 2011 · 143 citations · Full text

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov et al. · The American Journal of Gastroenterology · 2014 · 134 citations

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

Lior H. Katz, Javier P. Gisbert, Beth Manoogian et al. · Inflammatory Bowel Diseases · 2012 · 130 citations · Full text